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Aims Here, we aimed to determine the therapeutic effect of longevity-associated variant (LAV)-BPIFB4 gene therapy on
atherosclerosis.
...................................................................................................................................................................................................
Methods
and results
ApoE knockout mice (ApoE-/-) fed a high-fat diet were randomly allocated to receive LAV-BPIFB4, wild-type
(WT)-BPIFB4, or empty vector via adeno-associated viral vector injection. The primary endpoints of the study were
to assess (i) vascular reactivity and (ii) atherosclerotic disease severity, by Echo-Doppler imaging, histology and
ultrastructural analysis. Moreover, we assessed the capacity of the LAV-BPIFB4 protein to shift monocyte-derived
macrophages of atherosclerotic mice and patients towards an anti-inflammatory phenotype. LAV-BPIFB4 gene ther-
apy rescued endothelial function of mesenteric and femoral arteries from ApoE-/- mice; this effect was blunted by
AMD3100, a CXC chemokine receptor type 4 (CXCR4) inhibitor. LAV-BPIFB4-treated mice showed a CXCR4-
mediated shift in the balance between Ly6Chigh/Ly6Clow monocytes and M2/M1 macrophages, along with decreased
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T cell proliferation and elevated circulating levels of interleukins IL-23 and IL-27. In vitro conditioning with LAV-
BPIFB4 protein of macrophages from atherosclerotic patients resulted in a CXCR4-dependent M2 polarization
phenotype. Furthermore, LAV-BPIFB4 treatment of arteries explanted from atherosclerotic patients increased the
release of atheroprotective IL-33, while inhibiting the release of pro-inflammatory IL-1b, inducing endothelial nitric
oxide synthase phosphorylation and restoring endothelial function. Finally, significantly lower plasma BPIFB4 was
detected in patients with pathological carotid stenosis (>25%) and intima media thickness >2 mm.
...................................................................................................................................................................................................
Conclusion Transfer of the LAV of BPIFB4 reduces the atherogenic process and skews macrophages towards an M2-resolving
phenotype through modulation of CXCR4, thus opening up novel therapeutic possibilities in cardiovascular
disease.
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Introduction
Atherosclerosis, a multi-factorial disease influenced by genetic and
environmental factors, represents one of the leading causes of death
in industrialized society. As it is a slowly progressing disease, it is vital
to find new treatments able to halt plaque progression and the
underlying inflammatory substrate.1 In this regard, chemokines and
small chemotactic peptides represent a potential therapeutic target.1
Recent evidence indicates that the chemokine stromal-cell derived
factor-1 (SDF-1, also known as CXCL12) plays an important role in
reparative processes by binding to the C-X-C chemokine receptor
type 4 (CXCR4) on proangiogenic cells and leading them to sites of
tissue damage.2,3 Among myeloid cells, the high expression of
CXCR4 identifies transitional bone marrow precursors that replen-
ish the mature monocyte pool for peripheral responses.4 Here, the
recruitment of Ly6Chigh monocytes has resulted essential in plaque
regression through their proper differentiation into M2 macro-
phages.5 However, the precise role of CXCR4/CXCL12 in athero-
sclerosis remains controversial. Pharmacological disruption of
CXCR4 significantly aggravates diet-induced atherosclerotic lesion
development in ApoE-/- mice.2 In addition, a common allele variant
within the CXCR4 locus has been associated with atherosclerotic cor-
onary heart disease.3 However, it has been also reported that high
expression of CXCR4 in mouse heart increases infarct size, reduces
cardiac function and leads to recruitment of inflammatory cells.6
Furthermore, expression of CXCR4 and CXCL12 is reportedly
increased in Ly6C monocytes and macrophages within both stable
and unstable carotid atherosclerotic plaques compared with healthy
vessels, both at mRNA and protein levels.7
Long-living individuals (LLIs) delay or escape atherosclerosis-
related cardiovascular disease (CVD).8 We have previously found
that LLIs are enriched for a longevity-associated variant (LAV) in BPI
fold containing family B, member 4 (BPIFB4) and that LAV-BPIFB4,
when compared with wild-type (WT)-BPIFB4, is more phosphory-
lated at serine 75 and more cytoplasmic (due to its gained capacity to
bind 14-3-3), determining endothelial nitric oxide synthase (eNOS)
activation through a calcium/PKCa-mediated mechanism.9,10
Notably, systemic delivery of BPIFB4 to rodents with arterial hyper-
tension or limb ischaemia improved endothelial function, normalized
blood pressure, and accelerated revascularization, thus supporting
the novel concept of utilitarian transferability of the successful genetic
programme of centenarians to the treatment of CVD.10 We also
gathered initial evidence that LAV-BPIFB4 exerts an immunomodula-
tory activity, reducing T cell activation possibly through interference
with antigen presenting cells and the pro-inflammatory cytokines
TNF-a and IL-1b. Furthermore, our previous study showed that
mononuclear cells (MNCs) from LLIs are characterized by higher lev-
els of BPIFB4 and reduced CXCR4 expression than non-healthy
(frail) LLIs.11 Interestingly, lower CXCR4 expression in MNCs from
healthy LLIs is paired with greater membrane localization of
CXCR4,12 a hallmark of chemokine activation. In line with this finding,
BPIFB4 knockout by siRNA blunted the migratory response of circu-
lating pro-angiogenic cells to CXCL12.10 These seminal findings led
us to hypothesize that the transfer of LAV-BPIFB4 could be a viable
means to interfere with the immune-inflammatory features of vascu-
lar atherosclerosis.
To test this novel hypothesis, we performed LAV-BPIFB4 gene
therapy in ApoE-/- mice fed a high-fat diet, and evaluated the impact
on endothelial dysfunction and progression of the atherosclerotic
disease, focusing on CXCR4-dependent monocyte polarization as a
possible mechanistic mediator. Moreover, to assess the possible
translational aspects of BPIFB4 in humans, we investigated the correl-
ation between the plasma level of the protein and either carotid sten-
osis or intima media thickness (IMT) in two independent patient
cohorts.
Translational perspective
As the main risk factor for cardiovascular diseases (CVDs) is progressive ageing of the population, unravelling the secrets of healthy ageing
may be the only way to limit CVD disabilities. Here, we show that the favourable phenotype of long-living individuals can be transferred by
gene therapy with the longevity-associated variant (LAV) of BPIFB4 to animal models. Indeed, the ability of LAV-BPIFB4 to finely tune endothe-
lial function and pro/anti-inflammatory balance, as well as the fine correlation between a high BPIFB4 plasma level and a blunted atherogenic
process in the clinical setting, makes LAV-BPIFB4 a suitable candidate tool for the treatment of atherosclerosis and its related CVD
complications.
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Methods
Animal models
All animal studies were performed in accordance with approved proto-
cols by the IRCCS Neuromed Animal Care Review Board and by the
Istituto Superiore di Sanita`, Rome (number: 1163/2015-PR) and were
conducted according to EU Directive 2010/63/EU for animal experi-
ments. Animal models’ details and treatment are reported in
Supplementary material online.
Cloning, vector production and in vivo gene
therapy
Ten-week-old ApoE-/- male mice were treated with 1 1013 GC/kg of
AAV-GFP, AAV-WT-BPIFB4, or AAV-LAV-BPIFB4, as described in the
Supplementary material online.
Echo-Doppler analysis
Detailed procedure is available in the Supplementary material online.
Histology and lesion analysis
Detailed procedure is available in the Supplementary material online.
Transmission electron microscopy and
post-embedding immune-cytochemistry
Transmission electron microscopy method is available in the
Supplementary material online.
Ex vivo transfection of mouse vessels
Detailed procedure is available in the Supplementary material online.
In vitro studies on human monocyte-derived
macrophages
Detailed procedure is available in the Supplementary material online.
Cytokine detection
Cytokines were analysed by beads-based multiplex ELISA (LEGENDplex,
Biolegend, USA) as described in the Supplementary material online.
Patient cohorts
The patient enrolled for the evaluation of carotid stenosis, intima-media-
thickness, BPIFB4 plasma levels, and genotype characterization are
described in the Supplementary material online.
Ex vivo studies of human vessels
The study protocol was approved by the local ethics committees of
IRCCS Neuromed and done in accordance with the Declaration of
Helsinki. All participants gave written informed consent. Institutional re-
view board approval was obtained from IRCCS Neuromed (No.
20160106-1006). A detailed procedure is reported in the Supplementary
material online.
Western blotting
Western blotting was performed on pooled protein extracts from mice
vessels or on total segments of human vessels, as reported in the
Supplementary material online.
Statistical analysis
Statistical analyses are available in the Supplementary material online.
Results
LAV-BPIFB4 reduces endothelial
dysfunction
We examined the effects of LAV-BPIFB4 gene therapy in ApoE knock-
out mice, using GFP- and WT-BPIFB4-treated mice for comparison.
Genes were delivered using adeno-associated viral (AAV) vectors
injected into femoral arteries, with efficiency properly monitored in
liver, myeloid cells, plasma, and vascular cells (Supplementary mater-
ial online, Figures S1–S5 and Methods). In addition, each group was
randomized to receive a CXCR4 antagonist, AMD3100, or vehicle to
verify the effect of the receptor on the primary endpoints of the
treatment (Figure 1A). The primary endpoint indicates no difference
among groups with regard to KCl- or phenylephrine-induced vaso-
constriction and endothelium-independent relaxation to nitroglycer-
ine. Likewise, no difference was observed in the presence or absence
of the CXCR4 inhibitor (Figure 1B–D and Supplementary material on-
line, Figure S6A–D). In contrast, vessels obtained from ApoE knockout
mice treated with AAV-LAV-BPIFB4 showed a complete rescue of
acetylcholine-mediated endothelial vasorelaxation both in mesenter-
ic and femoral arteries (Figure 1E and Supplementary material online,
Figure S6D). Interestingly, AMD3100, a non-peptide antagonist of
CXCR4, abolished the beneficial effect of AAV-LAV-BPIFB4 gene ther-
apy (Figure 1E and Supplementary material online, Figure S6D).
Western blot analyses of mesenteric arteries explanted from
AAV-LAV-BPIFB4-treated mice showed an increase of total and phos-
phorylated (serine 75) BPIFB4 protein (Figure 1F).9 Likewise, AAV-
LAV-BPIFB4 increased the phosphorylation of eNOS at serine 1177
and of PKCa at threonine 497 (Figure 1F), in accordance with our pre-
vious published results.9 eNOS is required for CCL12/CXCR4-
mediated endothelial actions and different PKC isoforms mediate
CXCR4 phosphorylation/activation.13 These phosphorylation
changes were blunted by AMD3100 treatment, thus confirming the
importance of CXCR4 and upstream activators in LAV-BPIFB4-
induced vasorelaxation (Figure 1F). Of note, the action of AAV-LAV-
BPIFB4 was not dependent on total cholesterol or LDL circulating
levels, which remained similarly elevated in all after AAV-LAV-BPIFB4
treatment (Supplementary material online, Table S1). Moreover, LAV-
BPIFB4 exerted a protective effect on oxLDL-induced endothelial
dysfunction (Supplementary material online, Figure S7).
LAV-BPIFB4 halts vascular plaque
formation
We next considered the other primary endpoint of the in vivo study,
namely the progression of atherosclerosis as assessed by Echo-
Doppler and histology. Ultrasound scanning of aortic arch with epi-
aortic vessels revealed the presence lipid plaques in ApoE knockout
mice treated with AAV-GFP and AAV-WT-BPIFB4, whereas AAV-LAV-
BPIFB4 gene therapy reduced the formation of vascular plaques
(Figure 2A). The quantification of the abundance of lipid streaks in
aorta, which represent initial structural changes detectable in athero-
sclerosis, confirmed that LAV-BPIFB4 reduced vascular damage as
compared to all other groups (Figure 2B). Moreover, the effect of
LAV-BPIFB4 was lost in AMD3100-treated mice (Figure 2A and B), thus
corroborating the CXCR4-mediated protective role of LAV-BPIFB4
on the onset of the atherogenic process.
Longevity gene therapy prevents atherosclerosis 3
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arteries from ApoE knockout mice showed alterations in endothelial
cells, such as cytosolic derangement, diluted cytoplasm, detachment
of the endothelial membrane, and broken plasma membrane. Gene
therapy with AAV-LAV-BPIFB4 preserved the regular architecture of
the vascular endothelium, again through a CXCR4-dependent mech-
anism (Figure 2C–E).
An imbalance of the mononuclear phagocytic system within
the vascular wall is pivotal in influencing plaque initiation and
progression.14 Hence, we next verified the ability of LAV-BPIFB4
to interfere with the above mechanism by staining harvested
aortic arch with CD68þ, a marker highly expressed by mono-
cytes and lesional macrophages, and with a-smooth muscle actin
and collagen, which represent important compositional features
of the atherosclerotic lesions. Results indicated that LAV-BPIFB4
reduces macrophages infiltration without loss of smooth muscle
cells, a finding suggesting not only a slowing of the atherogenic
process but also plaque stabilization.15,16 The collagen compos-
ition in the aortic arch of LAV-treated mice, evaluated by Sirius
red positive area, showed a thicker fibrous cap than in vessels
from other treatments, indicating a role for LAV-BPIFB4 in con-
taining the onset and progression of the atherogenic processes
(Figure 2F). In agreement with these findings, femoral arteries
stained with the mono-macrophage marker MOMA-2 showed
a marked reduction of positive cells in vessels from AAV-
LAV-BPIFB- infected mice when compared with controls, an ef-
fect partially abolished by co-treatment with AMD3100
(Supplementary material online, Figure S5).
Figure 1 Overexpression of LAV-BPIFB4 improves the vascular reactivity of ApoE null mice fed, a high-fat diet, and a CXCR4 inhibitor abolishes
this protective effect. (A) Experimental protocol; (B) vascular response of ex vivo mesenteric arteries from ApoE knockout mice to potassium
(80 mmol/L KCl) and (C) the dose–responses to phenylephrine, (D) acetylcholine, and (E) nitroglycerine after 1 month of AAV-LAV-BPIFB4 treat-
ment. AAV-GFP was used as a control. Values are mean ± standard deviation of eight independent experiments. B, C, D, E two-way ANOVA fol-
lowed Tukey’s multiple comparisons test. Numbers next to the curve show adjusted P-values. (F) Representative western blot (left) and
densitometric analysis (right) conducted on mesenteric artery lysates. Values are mean ± standard deviation (N= 3). One-way ANOVA followed
Tukey’s multiple comparisons test. Numbers above square brackets show adjusted P-values.
4 A.A. Puca et al.
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LAV-BPIFB4 regulates the peripheral pool
of monocytes in a CXCR4-dependent
manner
The observed reductions of CD68þ cells at the aortic arch level and
of MOMA-2 positive cells in femoral arteries may reflect a redistribu-
tion of circulating monocytes in response to the treatment. Indeed,
as shown by western blot analysis, peripheral monocytes and pro-
genitor bone marrow myeloid cells expressed an enhanced level of
BPIFB4 after gene therapy (Supplementary material online, Figure
S5B). To test this, we next examined monocyte frequency in periph-
eral blood from mice treated with GFP, WT-BPIFB4, or LAV-BPIFB4. In
particular, we focused on the two major subsets of murine
monocytes: ‘classical’ Ly6Chigh and ‘non-classical’ Ly6Clow cells. Flow
cytometry analyses demonstrated LAV-BPIFB4 gene therapy causes a
reduction of Ly6Clow monocytes and an increase of Ly6Chigh mono-
cytes when compared with controls (Figure 3A).
Monocyte polarization has been attributed to changes in the oscil-
lation of CXCR4 expression on bone marrow precursor cells, which
serve for the replenishment of the peripheral pool of Ly6Chigh mono-
cytes.4 Additionally, a substantial portion of Ly6Chigh monocytes orig-
inates from the spleen.17 We confirmed that these central sites play a
role in the observed peripheral polarization induced by gene therapy.
In fact, LAV-BPIFB4, but not WT-BPIFB4 or GFP, increased the percent-
age of CXCR4þLy6Chigh cells in the bone marrow and spleen of
ApoE knockout mice. A similar trend was observed in peripheral
Figure 2 LAV-BPIFB4 gene therapy hinders plaque formation, preserves vascular endothelium integrity, and reduces monocyte/macrophages infil-
tration. (A) Ultrasound scanning of aortic arch with epi-aortic vessels in AAV-treated ApoE-/- mice fed a high-fat diet. LAV-BPIFB4-treated mice did
not have any plaques, whereas all those on the other treatments had calcified plaques (red arrows) and lipidic plaques (blue arrows). (B) Oil Red O
staining and quantitative analysis of atherosclerotic lesion size in the aorta. Oil Red O staining was quantified using ImageJ software. One-way
ANOVA followed by Tukey’s multiple comparisons test. Numbers above square brackets show adjusted P-values. (C–E) Representative micrographs
of endothelial cells from aorta (C), mesenteric (D), and femoral (E) arteries: (a) Vascular endothelium of the AAV-GFP group showed cytosolic de-
rangement (arrows) and broken plasma membranes (arrowheads); (b) these alterations were also evident in the group treated with the CXCR4 in-
hibitor. Diluted cytoplasm (arrow) and markedly condensed chromatin in the nucleus (N) was observed. (c) The endothelium was preserved by
gene therapy with LAV-BPIFB4. (d) AMD3100 contrasted the benefit of LAV-BPIFB4, with the endothelial cells showing a diluted cytoplasm (arrows)
and disruption of the plasma membrane (arrowheads); (e) The AAV-WT-BPIFB4-treated group presented with severely altered ultrastructure of the
endothelium; (f) AMD3100 administration conferred additional ultrastructural damage, with endothelial cell detachment from the elastic membrane
lamina (arrows). (F) Immunofluorescence staining of aortic arches from treated ApoE knockout mice, using the monocyte/macrophage marker
CD68þ, the smooth muscle cell marker aSMA, and Sirius Red staining to evaluate collagen (N= 4 per group). One-way ANOVA followed by
Tukey’s multiple comparisons test. Numbers above square brackets show adjusted P-values.
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.blood (Figure 3B). Importantly, AMD3100 contrasted the improved
effect of LAV-BPIFB4 on Ly6Chigh cell frequency, thus supporting a
role for CXCR4 in these phenomena (Figure 3C). Results of multiplex
bead-based immunoassay showed that LAV-BPIFB4 gene therapy
increases the peripheral blood levels of IL-23 and IL-27, effects con-
trasted by AMD3100 (Figure 3D and E).
LAV-BPIFB4 induces an enrichment of M2
splenic macrophages and reduces the
proliferative state of T cells
IL-23 and IL-27 are mainly secreted by monocytes and macro-
phages, and they have been recently implicated in suppression of
atherosclerosis, partly controlling myeloid cell accumulation.5,18–20
As Ly6Chigh conversion to M2 macrophages has been seen to
drive plaque regression in different models of atherosclerosis,5,17
we sought to examine whether LAV-BPIFB4 could shift the pheno-
type of macrophages towards the pre-resolving M2 (alternatively
activated) state. Due to the limited macrophage yield from the
vessel wall, we focused on readily available macrophages derived
from the spleen.21 Flow cytometry analysis of CD206/CD86, a
marker of the relative proportion of M2 vs. M1 cells, indicated
that LAV-BPIFB4 increased M2 monocytes in the spleen of ApoE
knockout mice (Figure 4A and B). LAV-BPIFB4-induced polarization
of monocytes towards an M2 phenotype was prevented by con-
comitant CXCR4 inhibition (Figure 4B).
M2 macrophages can reduce pro-inflammatory cytokine secretion
and dampen inflammatory responses.22,23 Therefore, we next com-
pared the proliferative state of CD4þ and CD8þ T cells in the
spleen and peripheral blood of ApoE knockout mice treated with
LAV-BPIFB4, WT-BPIFB4, or GFP (Figure 4C and D). Both LAV-BPIFB4
and WT-BPIFB4 reduced the abundance of Ki-67þ CD3 T cells, with
AMD3100 inhibiting this effect only in the LAV-BPIFB4 group in per-
ipheral blood compartment (Figure 4D). Looking at CD3 subfractions
mostly affected by these changes, we found that LAV-BPIFB4 specific-
ally reduced the abundance of proliferating cytotoxic CD8þ T
cells in the spleen and in a significant manner in peripheral blood
(Figure 4D).
Figure 3 LAV-BPIFB4 modulates monocyte dynamics in ApoE knockout mice. (A) Relative abundance of Ly6Chigh and Ly6Clow subsets in the per-
ipheral blood of treated mice (AAV-GFP, N= 5; AAV-LAV-BPIFB4, N= 5; AAV-WT-BPIFB4, N= 3). (B) Percentage of CD11bþLy6G-Ly6Cþmono-
cytes expressing CXCR4 in bone marrow, spleen, and blood (AAV-GFP, N= 5; AAV-LAV-BPIFB4, N= 5; AAV-WT-BPIFB4, N= 3). (C) Effect of
CXCR4 inhibitor on the frequency of peripheral blood Ly6Chigh monocytes (AAV-GFP, N= 5; AAV-LAV-BPIFB4, N= 5; AAV-WT-BPIFB4, N= 3;
GFP-AMD3100, N= 5; LAV-BPIFB4-AMD3100, N= 5; WT-BPIFB4-AMD3100, N= 3). (D and E) Plasma collected from all the mice groups indicated
above was assessed for circulating cytokine levels with bead-based multiplex ELISA. The relative concentrations of analytes are presented as a heat
map (D) or expressed as the mean ± standard deviation of each sample determination conducted in duplicate (E). Statistical analysis by two-way
ANOVA with post hoc Fisher’s Least Significant Difference (LSD) test was conducted. Numbers above square brackets show unadjusted LSD
P-values.
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In vitro exposure of PB-MNCs to
LAV-BPIFB4 protein induces M2
macrophage differentiation
In order to confirm a direct effect of LAV-BPIFB4 on macrophage po-
larization, we tested the effect of human recombinant LAV-BPIFB4
protein24 on CD14þ PB-MNCs collected from atherosclerotic
patients, which were induced to differentiate ex vivo into M1 or M2
macrophages, using a CellXVivoTM Kit, or into MPL macrophages,
after exposure to autologous plasma. After 72 h of cytokine priming,
cells were maintained in culture for an additional 72 h in the presence
of LAV-BPIFB4 recombinant protein or vehicle. As shown in Figure
5A, cells harvested at the end of the conditioning included M1 macro-
phages displaying the canonical CD14þ/CD206þ/CD163- pheno-
type, and M2 macrophages characterized by the CD14þ/CD206þ/
CD163þ phenotype. Flow cytometry analyses confirmed the ability
of MPL to induce an M1 phenotype, whereas LAV-BPIFB4 polarized
macrophages away from the M1 phenotype and towards a classical
M2 anti-inflammatory state (Figure 5A and B). Of note, co-treatment
with AMD3100 partially blunted the acquisition of the M2 phenotype
induced by LAV-BPIFB4. This confirms the direct involvement of
CXCR4 in LAV-BPIFB4’s polarizing effects (Figure 5C).
Finally, in order to strengthen the concept that LAV-BPIFB4 treat-
ment can modify the inflammatory milieu within the vasculature, we
measured the levels of pro- and anti-inflammatory mediators
secreted by organotypic cultures of human atherosclerotic vessels.
As shown in Figure 5D, stimulation with LAV-BPIFB4 protein reduced
the levels of pro-inflammatory IL-1b and TNF-a, while increasing
atheroprotective IL-33.25,26
Moreover, LAV-BPIFB4 improved endothelial-mediated vasorelax-
ation and eNOS phosphorylation of human atherosclerotic vessels
(Figure 5E).
Figure 4 Enhanced enrichment of M2 macrophages in the spleen of AAV-LAV-BPIFB4 ApoE knockout mice fed a high-fat diet. (A and B) CD45hi
CD11bþ F4/80þ splenic macrophages were additionally stained with flow cytometric markers CD206þ or CD86þ to discern the CD11bþ F4/80
þCD206 M2 type from CD11bþ F4/80þCD86 M1 type of splenic macrophages. A representative dot plot panel (left) is presented. The graph on
the right reports the mean ± standard deviation of ratios of M2 vs. M1 splenic macrophages (CD206/CD86 ratio) from all recipient mice (N= 3–5
per group). MFI stands for mean fluorescence intensity of selected markers. (C) Analysis of the proliferation of splenic and blood CD3þ T cells in
ApoE-/- mice infected with AAV-LAV-BPIFB4, AAV-WT-BPIFB4 or AAV-empty vector, treated or not with AMD3100. Representative dot plot
showing changes of percentage Ki-67 expression in both spleen and blood TCD3þ cells. (D) Bar graph reporting the percentage ± standard deviation
of Ki67þ, CD3þ gated T cells. Percentage of Ki-67þ expression in CD4þ and CD8þ T cell subsets from the spleen and the blood of recipient mice
were determined. The bar graph reports the percentage ± standard deviation. Statistical analysis by two-way ANOVA with post hoc Fisher’s Least
Significant Difference (LSD) test was conducted. Numbers above square brackets show unadjusted LSD P-values.
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..High plasma BPIFB4 associates with a
reduction of atherosclerotic risk
Starting form a population of 2606 individuals fully characterized in
the ‘Progressione della Lesione Intimale Carotidea’ (PLIC) study, we
focused on two groups of subjects stratified for the presence of sub-
clinical carotid atherosclerosis (respectively, lower or higher than
25% of carotid stenosis; N= 90) (Table 1), and evaluated plasma levels
of BPIFB4. Interestingly, our data revealed that in patients with no
Figure 5 In vitro conditioning with recombinant LAV-BPIFB4 protein leads to polarization of patient macrophages towards M2 phenotypes and
reduces the inflammatory milieu in the vessel wall. (A) Macrophages generated from peripheral blood monocytes from atherosclerotic patients
(N= 5) were cultured with or without recombinant LAV-BPIFB4 (18 ng/mL) for the last 72 h. Representative cytofluorimetric histogram profiles of
CD14, CD206, and CD163 protein levels at the cell surface of macrophages (viable gated CD68þ cells) polarized towards M1, M2, or MPL (autolo-
gous plasma) phenotypes. (B) (left panel) Histogram overlay for CD163 M2 markers in M1, M2, or MPL macrophages from control, untreated- (red
curve), and LAV-BPIFB4-treated cells (black curve) from a representative atherosclerotic patient. (right panel) The bar graph reports the mean fluor-
escence intensity (MFI) values ± standard deviation of CD163 on viable CD68þ gated cells. Two-way ANOVA followed by Tukey’s multiple compar-
isons test. Numbers above square brackets show adjusted P-values. (C) Representative histogram profiles of CD163 protein level on MPL cell surface
in controls and in cells treated with LAV-BPIFB4 (18 ng/mL) in the presence or absence of AMD3100 (20lM) for 72 h. Percentages of positive cells
are indicated in the upper right corner and are representative of four independent experiments. (D) Vessels from atherosclerotic patients (N= 5)
were incubated for 24 h at 37C in the presence or absence of 18 ng/mL LAV-BPIFB4. Conditioned medium was then assessed for cytokine secretion
with bead-based multiplex ELISA. The relative concentrations of analytes detected is presented as a heat map. Statistical comparisons were per-
formed with two-tailed Student’s t-test for simple comparisons. Numbers above square brackets show unadjusted P-values. (E) Vascular response of
ex vivo human atherosclerotic femoral arteries (upper) to increasing doses of acetylcholine, before and after treatment for 1 h with LAV-BPIFB4 re-
combinant protein (18 ng/mL) (N= 5); two-way ANOVA followed Tukey’s multiple comparisons test. Numbers reported on the curves show
adjusted P-values. (Bottom) representative western blots conducted on the studied human vessels.
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subclinical carotid atherosclerosis, the protein’s concentration was
significantly higher as compared to patients with carotid stenosis
(Figure 6A). The functional role of the circulating BPIFB4 was magni-
fied when examining its association with IMT stratification of a cohort
of 22 consecutively enrolled non-smokers, non-diabetics without
previous CV events and not on statin therapy, belonging to the
Campania Salute Network Registry, with hypertension as the singular
cardiovascular risk factor and an absence of other comorbidities
(Table 2). As shown in Figure 6B, BPIFB4 was significantly higher in
plasma from patients with IMT <2 mm,27 confirming a protective role
of high protein levels, a finding in line with what was previously
observed in the PLIC study. Moreover, genotype stratification ana-
lysis revealed that LAV carriers significantly more frequently had IMT
<2 mm cohort, and that in this cohort, LAV-BPIFB4 carriers had a
higher level of circulating BPIFB4 when compared with no-carriers
(Figure 6C and D).
Discussion
In recent years, different approaches have been developed to coun-
teract the progression of vascular atherosclerosis, including
cholesterol-level lowering and inflammation modulation. Owing to
the large numbers of inflammatory molecular and cellular mediators,
it is unlikely that blockade of a single cytokine will be therapeutically
effective. We report here new exciting results on the pleiotropic ac-
tivity of LAV-BPIFB4 on different mechanisms of the atherogenic pro-
cess. In particular, we demonstrate the efficacy of LAV-BPIFB4 in
contrasting endothelial dysfunction, plaque formation/progression,
inflammatory cytokine release, macrophage polarization, and T cell
activation, in a murine model of atherosclerosis. These benefits were
not associated with changes in the lipid profile. In addition, we pro-
vide ex vivo and in vitro evidence that these beneficial actions may ex-
tend to human vasculature until to be inversely associated to
subclinical index of atherosclerosis in selected patients.
Mechanistically, the effects of LAV-BPIFB4 seem to be attributable to a
CXCR4-dependent mechanism.
Investigation of CXCR4 and CXCL12 expression revealed that
the ligand and receptor are both up-regulated in stable and unstable
carotid atherosclerotic plaques, especially in macrophages, compared
with healthy vessels, both at the mRNA and protein level.7 It is, how-
ever, unclear if these expressional changes are pathogenic or com-
pensatory. Results from a recent study using a genetic approach
argue for the second possibility; in fact, in ApoE knockout mice fed a
high-fat diet, vascular-specific deletion of CXCR4 resulted in larger
atherosclerotic lesions compared with their relative control.28 In line
with this finding, reconstitution of LDLr(-/-) mice with autologous
bone marrow infected with lentivirus encoding SDF-1a antagonist or
CXCR4 degrakine, which affect proteasomal degradation of CXCR4,
led to progressive plaque development, intraplaque haemorrhage
and disease progression. Moreover, CXCR4 knockdown augmented
the adhesive capacity of neutrophils and the activation state of circu-
lating neutrophils.29,30 An epidemiological study followed by func-
tional validation with the CRISPR/Cas9 system confirmed that
genetic variation of CXCR4 can confer different susceptibility to cor-
onary artery disease.31 Altogether, these findings open new thera-
peutic perspectives for the treatment of atherosclerosis through the
targeting of the CXCL12/CXCR4 signalling pathway. Our study pro-
vides new evidence that this could be indeed a valuable option. In a
previous investigation, we showed that BPIFB4 and CXCR4 expres-
sion concordantly distinguished healthy LLIs and correlated with
maintained MNC migration towards CXCL12.12 Here, we demon-
strate that LAV-BPIFB4 gene therapy protects from atherosclerosis
through a mechanism involving the CXCR4 receptor in vascular cells
and MNCs.
Long-living individuals have the unique ability to age without expe-
riencing major CVD. The present study strengthens the novel con-
cept that the healthy phenotype of LLIs can be efficiently transferred
to murine models and cultured human tissues by the delivery of ei-
ther LAV-BPIFB4 or a recombinant protein. LAV-BPIFB4 gene therapy
succeeded in the two primary endpoints, namely improving endothe-
lial dysfunction and reducing adverse vascular effects in ApoE knock-
out mice fed a high-lipid diet. The benefit of LAV-BPIFB4 was also
evidenced at the ultrastructural level in vessels: it prevented the cyto-
solic derangement, cytoplasmic dilution, and irregular plasma mem-
brane observed in different vascular districts of control mice.
.................................................................................................
Table 1 Clinical characteristics of patients from the
PLIC study
Parameters PLIC population
(N5 90)
Age (years) 73 (70–77)
Gender (n, women) 50
Smoking habit (n, active) 18
BMI (kg/m2) 26.70 (23.90–29.60)
Waist (cm) 93.5 (87.0–99.2)
SBP (mmHg) 130 (120–140)
DBP (mmHg) 80 (70–85)
Anti-hypertensives (n, yes) 46
Fasting glucose (mg/dL) 93.00 (86.00–104.25)
Oral lowering therapies (n, yes) 5
Total cholesterol (mg/dL) 202.06 (30.91)
HDL (mg/dL) 59.04 (12.42)
Triglycerides (mg/dL) 88.00 (70.75–116.25)
LDL (mg/dL) 123.40 (29.30)
ApoA-I (mg/dL) 151.64 (18.78)
ApoB (mg/dL) 105.93 (19.91)
Statins (n, yes) 0
ALT (U/I) 16 (13–21)
AST (U/I) 18 (16–22)
GGT (U/I) 20 (14–27)
Creatinine (mg/dL) 0.85 (0.76–0.95)
GFR (Cockcroft–Gault formula,
mL/min/1.73 m2)
69.35 (17.65)
Previous CVD (n, yes) 19
Data are reported as mean ± standard deviation for normally distributed varia-
bles (Shapiro–Wilk test) or median (interquartile range) for non-normally distrib-
uted variables (see Supplementary material online, Statistical Analysis section).
ALT, alanine aminotransferase; ApoA-I, apolipoprotein A1; ApoB, apolipoprotein
B; BMI, body mass index; CVD, cardiovascular disease; DBP, diastolic blood pres-
sure; GGT, gamma-glutamyltransferase; HDL, high-density lipoproteins; LDL,
low-density lipoproteins; SBP, systolic blood pressure.
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Interestingly, LAV-BPIFB4 gene therapy did not affect the serum chol-
esterol profile, but it did contrast the ability of oxidized cholesterol
to induce endothelial dysfunction by positively modulating the inflam-
matory/immune background of atherosclerosis.32
In line with this, LAV-BPIFB4 redistributed the pool of monocyte
subpopulations, redirecting them towards a pro-resolving phenotype.
This was reflected by the increased abundance of CXCR4þLy6Chigh
monocytes in bone marrow and spleen, the two major tissue reser-
voirs of monocytes available to mobilize towards injured tissues. In
the margination process, CXCR4 is considered the retention force in
the vasculature. Therefore, we speculate that the higher level of
CXCR4 in blood Ly6Chigh monocytes after LAV-BPIFB4 treatment in
mice may finely tune the transit time into the circulation, completing
a protective intravascular differentiation process. In this context, re-
cent studies have provided new interesting insight into the regulatory
mechanisms of monocytosis relevant to atherosclerosis. Consistent
with their functionally distinct immunological roles, newly recruited
Ly6Chigh but not Ly6Clow monocytes uniquely differentiate into pro-
resolving M2 macrophages, driving murine atherosclerotic regression
at the early stages of the disease.5,32 Accordingly, we documented an
enrichment of M2 splenic macrophages, which can contribute to
dampen T cell activation and proliferation in a CXCR4-dependent
manner, as AMD3100 counteracted most of the LAV-BPIFB4-medi-
ated actions on the mono-macrophage compartment. This latter re-
sult is in keeping with the reported ability of CXCR4 to promote the
acquisition of the M2 phenotype in healthy monocyte-derived mac-
rophages.33 Furthermore, the described influence of LAV-BPIFB4 on
Figure 6 High plasma BPIFB4 detected in LAV-carrier patients is associated with reduced carotid stenosis and IMT < 2mm. Graphs showing correl-
ation between: (A) BPIFB4 plasma level in patients with carotid stenosis >25% (N= 48) and in patients with no carotid atherosclerosis (N= 42). (B)
BPIFB4 level in patients stratified for IMT <2 mm (N= 14) vs. IMT >2 mm (N= 8). (C and D) Correlation between BPIFB4 protein levels with intima
media thickness (C) and with plasma concentration (D) after genotype stratification of WT- or LAV-carrier patients. Results are presented as mean ±
standard deviation and were analysed by two-tailed non-parametric Mann–Whitney test. Numbers above lines show unadjusted P-values.
.................................................................................................
Table 2 Characteristics of hypertensive patients from
the Campania Salute Study
Parameters CS population
(N522)
Clinical characteristics
Age (years) 69 ± 7
Sex (male/female) 11/14
SBP (mmHg) 143.6 ± 15.7
DBP (mmHg) 89.56 ± 12.5
Weight (kg) 76.36 ± 11.9
Height (cm) 163.1 ± 9.5
Cholesterol (mg/dL) 212.8 ± 47.4
HDL (mg/dL) 55.25 ± 10.9
TG (mg/dL) 130.5 ± 60.4
Glycaemia (mg/dL) 96.46 ± 12.1
Creatinine (mg/dL) 0.905 ± 0.19
Medication (%)
b-blocker 5 (20)
Ang-II receptor antagonist 12 (48)
ACE-inhibitor 8 (32)
Diuretics 11 (44)
CCB 9 (36)
Data are reported as mean ± standard deviation.
CCB, amlodipine/olmesartan medoxomil; DBP, diastolic blood pressure; HDL,
high-density lipoproteins; SBP, diastolic blood pressure; TG, triglycerides.
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..the myeloid compartment is in agreement with the recorded in-
crease in IL-23 and IL-27 in peripheral blood in the mouse model.
Indeed, both cytokines modulate endothelial cell activation and mye-
loid cell recruitment at early and advanced stages of atherosclerosis,
limiting the deleterious effects of the pathological events.34,35
Our study also provides compelling in vitro evidence that the LAV-
BPIFB4 protein can exert similar beneficial effects in redirecting
human monocyte-derived macrophages from an M1 pro-inflamma-
tory to an M2 anti-inflammatory phenotype, as well as correcting the
balance of cytokines, increasing eNOS phosphorylation, and improv-
ing endothelial function in human atherosclerotic vessels. All these
beneficial events observed in the different anatomical districts might
be finely orchestrated by the circulating levels of BPIFB4, which was
found significantly increased in plasma of AAV-LAV-BPIFB4-treated
mice after 1 month of gene therapy. Indeed, the undetectable level of
GFP protein both in myeloid cells and aorta led us to speculate a by-
stander action of circulating BPIFB4 on the immune compartment
and in vascular cells after its proper production and rapid secretion
by transduced liver cells (Take home figure). Accordingly, elevated
plasma concentration of the protein associated with protection
against the onset of the atherosclerotic disease, regardless of risk fac-
tors, in two independent patient cohorts, a finding corroborating the
protective role of the LAV-BPIFB4 isoform and strengthening its
translational relevance.
Conclusion
In conclusion, the novel findings from this study highlight the potential
of LAV-BPIFB4 in contrasting vascular and immune features of
atherosclerosis. This supports an alternative therapeutic vision of the
management of CVDs. Hence, we foresee that LAV-BPIFB4 therapy
could be a viable option to delay the occurrence of age-related car-
diovascular disease, replicating successful, healthy longevity in popula-
tions at risk.
Supplementary material
Supplementary material is available at European Heart Journal online.
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